Arca
Skip to content

Warning Letter to PharmScript, LLC

Drugs. See PharmScript, LLC's company page or this site's inspections.

On Jul 29, 2019, FDA's CDER sent PharmScript, LLC a warning letter.

  • Letter date: Jul 29, 2019
  • Issued by: CDER
  • Closeout: —

The Letter

As posted on FDA.gov ↗; cited 21 CFR sections link to their page.

Dear Mr. Segal:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [WL #17-NWJ-11; dated August 23, 2017]. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely, /S/ Diana Amador-Toro Program Division Director/District Director OPQO Division I New Jersey District Office

Record

Recipient
Michael Segal
FDA site ID (FEI)
3012837733
Cited
—

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.